Document:

Exhibit
10.1

 

SECOND AMENDMENT TO EXCLUSIVE LICENSE
AGREEMENT

 

This SECOND AMENDMENT
TO THE EXCLUSIVE LICENSE AGREEMENT (“Second Amendment”), is made effective as of March 3, 2021 (the “Effective
Date”), by and between the University of Miami, a Florida not-for-profit corporation (“UNIVERSITY”), and Longeveron,
Inc, a Delaware corporation, whose principal place of business is at 1951 NW 7th Avenue, Miami, Florida 33136 (the
“LICENSEE”). UNIVERSITY and Licensee are referred to herein as, the “Parties” and each, individually,
a “Party”.

 

WHEREAS, the Parties
entered into an EXCLUSIVE LICENSE AGREEMENT dated November 20, 2014;

 

WHEREAS,
the Parties amended the EXCLUSIVE LICENSE AGREEMENT by AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT dated December 11, 2017 (the “First
Amendment”);

 

WHEREAS, the Parties
executed a Letter of Intent dated September 9, 2020 (the “Letter of Intent”) to memorialize, among other items, their
intent to execute an amendment to the EXCLUSIVE LICENSE AGREEMENT;

 

WHEREAS, the Parties now wish to amend
the EXCLUSIVE LICENSE AGREEMENT, as amended by the First Amendment thereto pursuant to, in accordance with, and in substitution
of the Letter of Intent; and

 

NOW, THEREFORE, for
good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound
hereby, the Parties agree as follows:

 

		1.	Section 3.1(a) of the EXCLUSIVE LICENSE AGREEMENT is hereby
amended to increase the license issue fee due to UNIVERSITY. In this respect, LICENSEE agrees to pay UNIVERSITY an additional
fee of $100,000 to defray patent costs, with $70,000 due within thirty (30) days of the Effective Date, and the remainder to be
paid in equal installments of $7,500 on the 2nd, 3rd, 4th, and 5th year anniversaries
of the Effective Date.

 

		2.	Section 3.4 of the EXCLUSIVE LICENSE AGREEMENT is hereby amended to increase the “partial
consideration” for the license granted pursuant to the EXCLUSIVE LICENSE AGREEMENT, such that LICENSEE will issue 110,387
shares of the LICENSEE’S Class A Common Stock to UNIVERSITY (the “New Shares”) e. For the avoidance of doubt,
the New Shares shall be in addition to the shares of Class A Common Stock received by UNIVERSITY for the Series C Common Units
already provided to UNIVERSITY under Section 3.4 of the EXCLUSIVE LICENSE AGREEMENT in the LICENSEE’S conversion to a corporation
(the “Conversion”). The New Shares represent the number of shares of Class A Common Stock that would have been received
in the Conversion by a holder of one percent (1%) of the outstanding Series C Common Units of LICENSEE immediately prior to the
Conversion.

 

    Page 1 of 6

     

    

 

		3.	Section 4.3(d) of the EXCLUSIVE LICENSE AGREEMENT is amended to modify the amount and scope of
the milestone payments to be made by LICENSEE to UNIVERSITY. In this respect, the Parties agree that UNIVERSITY is instead entitled
to the following milestone payments: (a) for the sake of clarity, there shall be no payment due upon completion of Phase II clinical
trials for the Product; (b) a one-time payment of $500,000, payable within six (6) months of the completion of the first Phase
III clinical trial for the Product by LICENSEE (based upon the date of final data unblinding); (c) a one-time payment of $500,000
payable within six (6) months of the receipt by LICENSEE of approval for the first new drug application (“NDA”), biologics
license application (“BLA”), or other marketing or licensing application for the Product (as defined in the EXCLUSIVE
LICENSE AGREEMENT); and (d) a one-time payment of $500,000 payable within six (6) months of the first sale following Product approval.
For the avoidance of doubt, the use of “approval” in this section 4.3(d) of the EXCLUSIVE LICENSE AGREEMENT is modified
to refer to Product approval, licensure, or other marketing authorization by the U.S. Food and Drug Administration (“FDA”),
or any successor agency.

 

		4.	Subject to Section 2.2 of the EXCLUSIVE LICENSE AGREEMENT (retaining rights), the “Technology Rights” exclusively
licensed to LICENSEE pursuant to the EXCLUSIVE LICENSE AGREEMENT are hereby modified, to the extent not already included or acquired
by licensee, to include:

 

		a.	the investigational new drug (“IND”) application known as BB-IND 15679, “AllogeneiC Human Mesenchymal Stem
Cells (hMSC) in Patients with Aging FRAiLTy via IntravenoUS Delivery” (the “CRATUS IND”);

 

		b.	all research data contained in and arising from the CRATUS IND (the “CRATUS Data”);

 

		c.	UMP-106 invention disclosure, “A method to restore vascular health with infusions of stem cells”;

 

		d.	PCT International Patent App. No. PCT/US2015/060624, entitled “Material and Methods for Treating Endothelial Dysfunction
and Methods for Monitoring Efficacy of Therapy in a Subject,” filed on November 13, 2015, as well as all national phase counterparts
thereof and all applications related by common priority; and

 

		e.	BB-IND 16045, “Allogeneic hMSC Injection in Patients with Hypoplastic Left Heart Syndrome (ELPIS)” (“HLHS
IND”), including all research data contained in and arising from the HLHS IND (the “HLHS Data”).

 

De-identified and anonymized data, know-how, protocols, standard
operating procedures, statistical reports and correspondence with regulatory agencies and institutional review boards (“IRBs”),
developed and collected in the conduct of the following clinical studies conducted by UNIVERSITY will be transferred to LICENSEE
via the UNIVERSITY office of the vice provost for innovation. For the sake of clarity, with regard to the CRATUS IND and the HLHS
IND, LICENSEE’s ownership and sponsorship and the information to be transferred will be clarified and the mechanism for transfer
will be detailed in a separate transfer agreement through the office of the vice provost for innovation.

    Page 2 of 6

     

    

 

	Study Title	ClinicalTrials.gov or IND Identifier	Principal Investigator(s)
	
        AllogeneiC Human Mesenchymal Stem Cells
        (hMSC) in Patients with Aging FRAiLTy via IntravenoUS Delivery (CRATUS)

        (“CRATUS IND”)
	
         

        BB-IND 15679
	
         

         

         

        Joshua M. Hare

	
        Allogeneic hMSC Injection
        in Patients with Hypoplastic Left Heart Syndrome (ELPIS)

        (“HLHS IND”)
	
         

        BB-IND 16045

 

		5.	An exclusive option to obtain an exclusive license for two years from the Effective Date, extendable with mutual consent, is
granted to LICENSEE for:

 

		a.	the HLHS IND with ckit+ cells; and

 

		b.	UMP-438 titled “Method of Determining Responsiveness to Cell Therapy in Dilated Cardiomyopathy.”

 

If LICENSEE exercises this exclusive option,
in whole or in part, then at the time of the exercise of any such license, LICENSEE shall pay outstanding patent costs for the
technologies licensed, but LICENSEE shall not pay any other costs or fees for the license on (a) and/or (b) above. During the option
period, decisions related to ongoing patent costs will be agreed upon between the Parties.

 

		6.	Appendix A of the EXCLUSIVE LICENSE AGREEMENT is hereby revised and attached hereto to reflect
the amended scope of “Technology Rights” as agreed upon under this Second Amendment. For the avoidance of doubt, as
of the Effective Date, Appendix A attached hereto replaces in full any and all previous versions of Appendix A that existed before
the Effective Date.

 

		7.	Except for the Licensed Technology, no inventions, intellectual property, works, data, and/or processes
of UNIVERSITY are licensed to LICENSEE hereunder. LICENSEE must seek and obtain the approval of UNIVERSITY to use—for any
and all purposes— other UNIVERSITY inventions, intellectual property, works, data, and/or processes not included in the EXCLUSIVE
LICENSE AGREEMENT.

 

		8.	For the sake of clarity, i) UNIVERSITY retains the right to undertake research with the Licensed
Technology, and any newly generated data or inventions that are developed with UNIVERSITY resources will belong to UNIVERSITY and
are not part of the EXCLUSIVE LICENSE AGREEMENT, the First Amendment, or this Second Amendment; ii) any newly generated data or
inventions that are developed with LICENSEE’s resources will belong to LICENSEE and are not included in this EXCLUSIVE LICENSE
AGREEMENT; (iii) notwithstanding anything to the contrary, the definition of Net Sales, Products and Processes shall remain as
in the original EXCLUSIVE LICENSE AGREEMENT.

 

    Page 3 of 6

     

    

 

		9.	Entire Agreement. The EXCLUSIVE LICENSE AGREEMENT and First Amendment, as amended by this
Second Amendment, constitutes the entire agreement between the Parties with respect to the subject matter hereof and thereof and
supersedes all previous written or oral representations, agreements, understandings, and negotiations with respect thereto, including
the Letter of Intent.

 

		10.	Choice of Law. This Second Amendment shall be governed by and interpreted in accordance
with the laws of the State of Florida, excluding any principle of conflict or choice of law provisions.

 

		11.	Representations and Warranties. Both Parties hereby represent and warrant to each other
as follows:

 

		a.	Each Party has taken all necessary action to authorize the execution, delivery and performance
of this Second Amendment;

 

		b.	This Second Amendment has been duly executed and delivered by each of the Parties and constitutes
each Party’s legal, valid, and binding obligations, enforceable in accordance with its terms, except as such enforceability
may be subject to (A) bankruptcy, insolvency, reorganization, fraudulent conveyance or transfer, moratorium or similar laws affecting
creditors’ rights generally and (B) general principles of equity (regardless of whether such enforceability is considered
in a proceeding at law or in equity);

 

		c.	Each party represents that with respect to itself, no consent, approval,
authorization or order of, or filing, registration, or qualification with, any court or governmental authority, or third party
is required in connection with the execution, delivery, or performance of this Second Amendment; and

 

		d.	To the best of each Party’s knowledge, both Parties have performed all of their respective
obligations under the EXCLUSIVE LICENSE AGREEMENT and First Amendment (except to the extent such obligations are amended by the
terms of this Second Amendment), and neither Party has knowledge of any event which with the giving of notice, the passage of time,
or both would constitute a breach of the EXCLUSIVE LICENSE AGREEMENT or First Amendment by the other Party.

 

		12.	Counterparts. This Second Amendment may be executed in any number of counterparts, each
of which so executed and delivered shall be an original, but all of which shall constitute one and the same instrument.

 

		13.	In all other respects, the EXCLUSIVE LICENSE AGREEMENT and the First Amendment thereto, shall remain
in full force and effect in accordance with all other terms and conditions specified therein.

 

		14.	This Second Amendment shall be effective from and after the Effective Date.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK]

 

    Page 4 of 6

     

    

 

IN WITNESS WHEREOF, and intending to be
legally bound, each of the Parties hereto has caused this Second Amendment to be executed as of the date first set forth above.

 

	UNIVERSITY:	 	LICENSEE:
	 	 	 
	University of Miami	 	Longeveron, Inc.
	 	 	 
	By: 	/s/ Norma Sue Kenyon	 	By:	/s/ Geoff Green
	Name: 	Dr. Norma Sue Kenyon	 	Name:	Geoff Green
	Title:	Vice Provost for Innovation	 	Title: 	CEO

 

    Page 5 of 6

     

    

 

APPENDIX A

Technology Rights

 

		A.	The term “Technology Rights,” as used in this Agreement, refers specifically and only to the following:

 

		1.	Under University of Miami Case No. UMP-133:

 

		a.	Any and all know-how specifically related to the development of the culture- expanded, mesenchymal stem cells for aging-related
frailty used at the Interdisciplinary Stem Cell Institute of the University (“IMSCs”)

 

		b.	All standard operating procedures (“SOPs”) used to create the IMSCs.

 

		c.	Any and all data supporting isolation, culture, expansion, processing, cryopreservation and management of the IMSCs.

 

		d.	For the sake of clarity, 1(a), (b) and (c) refer to the know-how, IMSCs SOPs, and data originally licensed to Longeveron. Any
improvements, modifications or derivatives developed by UM thereafter shall belong to UM, and any improvements, modifications,
or derivatives developed by LICENSEE thereafter shall belong to LICENSEE.

 

		2.	(a) the investigational new drug (“IND”) application known as BB-IND 15679, “AllogeneiC Human Mesenchymal
Stem Cells (hMSC) in Patients with Aging FRAiLTy via IntravenoUS Delivery” (the “CRATUS IND”);

 

		(b)	all research data contained in and arising from the CRATUS
IND (the “CRATUS Data”);
	 	 	 

		(c)	UMP-106 invention disclosure, “A method to restore
vascular health with infusions of stem cells”;
	 	 	 

		(d)	PCT International Patent App. No. PCT/US2015/060624, entitled
“Material and Methods for Treating Endothelial Dysfunction and Methods for Monitoring Efficacy of Therapy in a Subject,”
filed on November 13, 2015, as well as all national phase counterparts thereof and all applications related by common priority;
and
	 	 	 

		(e)	BB-IND 16045, “Allogeneic hMSC Injection in Patients
with Hypoplastic Left Heart Syndrome (ELPIS)” (“HLHS IND”), including all research data contained in and arising
from the HLHS IND (the “HLHS Data”).

 

An exclusive option of two years, extendable with mutual consent,
is granted for:

 

		(f)	the HLHS IND with ckit+ cells; and
	 	 	 

		(g)	UMP-438 titled “Method of Determining Responsiveness
to Cell Therapy in Dilated Cardiomyopathy”.

 

If LICENSEE exercises this exclusive option, in whole or
in part, then at the time of the exercise of any such license, LICENSEE shall pay outstanding patent costs for the
technologies licensed, but LICENSEE shall not pay any other costs or fees for the license on (f) and/or (g) above. During the
option period, decisions related to ongoing patent costs will be agreed upon between the Parties.

 

		B.	For avoidance of doubt, UNIVERSITY acknowledges and agrees
that the term “Technology Rights” does not include (i) any and all future New Drug Applications (NDAs), Biologics
License Applications (BLAs), and any and all future/issued patents, patent applications, divisional or continuation, domestic
or foreign, in whole or in part applications, arising from those certain Investigational New Drug (IND) applications filed with
the U.S. Food and Drug Administration under BB-IND 15679, “Allogeneic Human Mesenchymal Stem Cells (hMSC) in Patients with
Aging FRAilTy via Intravenous Delivery (CRATUS),” a Phase I/II, randomized, blinded and placebo-controlled trial to evaluate
the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty, and under
BB-IND 16045; and (ii) information relating to BB-IND 16045 and/or BB-IND 15679 following transfer of that information pursuant
to Section 4 of this Agreement.

 

		C.	For avoidance of doubt, the UNIVERSITY shall be entitled
to royalties and consideration hereunder to the extent that the Technology Rights detailed in Section A of this Amendment result
in the development of Products or Processes that arise from or otherwise use or incorporate the Technology Rights.

 

 

Page 6 of 6Exhibit 10.2

 

COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT

 

This COLLABORATIVE
RESEARCH AND DEVELOPMENT AGREEMENT (the “Agreement”) is entered into as of the 3rd day of
March, 2021 (the “Effective Date”) by and between Longeveron, Inc, a corporation organized under
the laws of the State of Delaware and having offices at 1951 NW 7th Avenue, Miami, Florida 33136
(“Longeveron”), and University of Miami, a not-for-profit corporation having an office at 1320 S.
Dixie Highway, Gables One Tower #650, Locator Code 2960, Coral Gables, FL 33146 (the “Institution”). Each
of Longeveron and Institution are sometimes referred to herein as a “Party” or, jointly, as the
“Parties.”

 

WHEREAS,
the Parties wish to collaborate and maintain a positive and productive research and business relationship in the area of cell therapies
and regenerative medicine;

 

WHEREAS,
the Parties wish to enter into an agreement that delineates the Parties’ obligations and responsibilities with respect to
mutual projects and formal transfer of Institution Innovations between Institution and Longeveron;

 

WHEREAS,
the Parties agree to establish this Agreement for the above mentioned purposes;

 

NOW,
THEREFORE, in consideration of the mutual promises and covenants contained herein, and intending to be legally bound hereby,
the Parties agree as follows:

 

		1.	Collaboration.

 

		a.	The Parties desire to collaborate during the Term (as hereinafter defined)
in connection with various research and development initiatives, including but not limited to, preclinical research, animal trials,
and human clinical trials (each a “Study,” together the “Studies”).

 

		b.	Given the above, this Agreement establishes the general terms and conditions applicable to all
Studies between Longeveron and Institution.

 

		i.	The specific requirements for each Study shall be set forth in a work order
containing the specifics for the applicable Study (“Work Order”), which Work Order shall be substantially similar to
the form attached hereto as Exhibit A. Each Work Order shall identify the specific protocol or scope of work for the Study,
the Investigator who shall conduct the relevant Study (“Principal Investigator”), the payments due from Longeveron,
and the deliverables to be provided to Longeveron through Institution’s conduct of such Study. The terms of this Agreement
are incorporated into each Work Order by reference. In the event of any inconsistency between the Work Order and this Agreement,
the terms of this Agreement shall control unless the Work Order states it is to control and states with specificity the terms meant
to be changed, in which event such conflicting or inconsistent terms shall only be controlling with respect to that particular
Work Order.

 

    1 

     

    

 

		ii.	This Agreement shall not apply to a Study, and there shall be no agreement
between the Parties with respect to a Study, unless and until (i) a Work Order setting forth the Study-specific activities and
terms has been executed by authorized representatives of Longeveron and the Institution, and (ii) the applicable Principal Investigator,
an employee of Institution, has read and acknowledged his/her responsibilities under such Work Order.

 

		iii.	Budget. In full consideration for the performance of a Study by
Institution, Longeveron shall pay Institution those fees, expenses and costs, at such times and in accordance with such timelines
as are set forth in the budget (“Budget”) in the applicable Work Order. Institution and Principal Investigators shall
use funds paid by Longeveron solely to conduct the applicable Study under this Agreement.

 

		iv.	Provision of Investigational Product. For any Study where an Investigational
Product, as defined in the applicable Work Order and its schedules, is being tested, Longeveron shall provide Institution, at no
charge, such quantities of the Investigational Product required for the applicable Study. Institution shall safeguard the Investigational
Product with the same degree of care used for its own property, and shall, following completion or termination of the applicable
Study, return or otherwise dispose of any unused Investigational Product, at Longeveron’s expense, in accordance with Longeveron’s
instructions and applicable law.

 

		c.	Longeveron and Institution shall comply with and conduct all aspects of
this Agreement and any Study in compliance with all applicable federal, state, and local laws and regulations.

 

		2.	Disclosure.

 

		a.	Longeveron will disclose all proposed written agreements prior to their
execution between the Parties after the Effective Date of this Agreement, whether through the Office of Research Administration,
Business Services or other Institution units, to the Institution Provost or Provost’s designee. Institution will evaluate
and review each agreement in the context of existing Longeveron agreements to ensure full transparency and alignment between the
Parties. Inadvertent failure to disclose a proposed written agreement shall not be a material breach of this Agreement. However,
should Longeveron determine after the fact that there is a proposed or actual written agreement that had not been disclosed, then
Longeveron shall disclose such agreement to the Institution within five business days of discovery of the lack of disclosure by
an officer of Longeveron.

 

    2 

     

    

 

		b.	In the event that Longeveron plans to enter into a new disease indication
and Longeveron believes that it would be appropriate to share this information with Institution to ensure that there will not be
a conflict or appearance of conflict between Institution and Longeveron, and with the goal of managing any conflict or appearance
of conflict between Institution and Longeveron, Longeveron may choose, at its sole discretion, to confidentially disclose its intent
to work on the new disease indication to the Provost or his/her designee.

 

		i.	The Provost or his/her designee, in consultation with Longeveron, will determine whether or not
work in the same disease indication is occurring at Institution and whether there may be a conflict or perceived conflict.

 

		ii.	Longeveron may choose to work with Institution on the new disease indication.

 

		iii.	If Longeveron chooses not to work with Institution on the new disease indication,
Longeveron will use its best efforts to ensure that no Institution grants, Institution data (unless publicly available without
breach of Section 5 of this Agreement), or other previously unlicensed Institution Innovations will be utilized by Longeveron in
connection with its new disease indication.

 

		iv.	In addition to the above, Longeveron also agrees to confidentially disclose, at its sole discretion,
when it believes there may be a conflict or perceived conflict, any and all work (e.g., research, studies, clinical trials,
etc.) it is performing, or intends to perform, with entities that are currently collaborating with Institution personnel to perform
or assist with ongoing research and clinical trials involving (a) culture-expanded, mesenchymal stem cells for aging-related frailty
developed and used by Institution’s Interdisciplinary Stem Cell Institute (the “IMSCs”) and/or (b) any other
Institution Innovations licensed to Longeveron.

 

		v.	University and Institution each warrant that their respective employees are bound by, and obligated
to perform under, their guidelines, policies and procedures, including any required conflict of interest and innovation disclosures.
In those cases in which any person is employed by both University and Institution, then in such cases, the person shall be bound
by the guidelines, policies and procedures of both employers.

 

		vi.	For the avoidance of doubt, Longeveron is not required to obtain Institution’s
authorization to proceed with the work described in this Section 2(b). Rather, this Section is aimed at making best efforts to
ensure that all conflicts or perceived conflicts of interest are properly managed.

 

    3 

     

    

 

		3.	Steering Committee. A
                                         Steering Committee (the “CRADA Committee”) will be established to govern
                                         the implementation of the CRADA, as follows:

 

		a.	The CRADA Committee will include three (3) voting representatives from
each Longeveron and Institution (for a total of six (6) members), and the Parties will each designate a Lead Representative to
serve on the CRADA Committee.

 

		b.	The Provost or his/her designee will manage and run the CRADA Committee meetings as a non-voting
member.

 

		c.	Independent of funding source, the CRADA Committee will establish a formal
process for agreed-upon sharing and transfer of data, investigational new drug applications (“INDs”), materials or
other Innovations from Institution to Longeveron within sixty (60) days of the Effective Date. To facilitate this process, Institution
and Longeveron will execute a Business Associate Agreement (“BAA”), material transfer agreement (“MTA”),
or other agreement(s), as appropriate.

 

		d.	Once the formal procedures are established, the CRADA Committee will meet
twice a year and/or as needed to review and discuss:

 

		i.	Proposed Studies to be sponsored by Longeveron;

		ii.	Other Institution Innovations that Longeveron is interested in licensing;

		iii.	Longeveron inventions and Longeveron Innovations that UM would be interested in using for its
research purposes; and

		iv.	Plans to ensure the protection of the rights of all innovators.

 

		4.	Term. The term of this Agreement shall commence upon the Effective
Date of this Agreement and terminate five (5) years thereafter (the “Term”) unless sooner terminated in accordance
with Section 8 herein. This Agreement shall be renewable upon the mutual written agreement of both Parties (“Renewal Period”).
Upon expiration of this Agreement and any Renewal Periods, no new Work Orders shall be entered into between the Parties. Notwithstanding
the foregoing, the terms of this Agreement and any Renewal Period shall survive until the completion of each Work Order(s) executed
prior to expiration of this Agreement or any Renewal Period with respect to that Work Order, and such Work Order(s) shall continue
to be subject to this Agreement or any Renewal Period until such Work Order(s) are completed or terminated in accordance with the
terms therein.

 

    4 

     

    

 

		5.	Confidentiality.

 

		a.	Each of the Parties acknowledges that it may be necessary to disclose information to the
                                                                                                       other which the disclosing Party considers proprietary or confidential in order for each of the Parties to perform its
                                                                                                       obligations under this Agreement (“Confidential Information”). To preserve the proprietary or confidential nature
                                                                                                       of such Confidential Information, each Party as a disclosing Party agrees: (i) to use reasonable efforts to clearly mark the
                                                                                                       term “CONFIDENTIAL” on its Confidential Information upon disclosure to the other Party when such disclosure is
                                                                                                       made in tangible form or (ii) in the case of oral or other intangible disclosures, to use reasonable efforts to indicate the
                                                                                                       confidential nature of such information in a written summary clearly marked as “CONFIDENTIAL” and transmitted to
                                                                                                       the other Party within thirty (30) days of the intangible disclosure provided that, the failure to do either (i) or (ii)
                                                                                                       above shall not destroy the confidential nature of the Confidential Information when the confidential nature would be
                                                                                                       reasonably recognized by the receiving Party from the subject matter or subject type of the information disclosed and such
                                                                                                       information shall be deemed confidential.

 

		b.	The Parties shall protect and maintain the confidentiality of the Confidential
Information and shall use the same degree of care to protect the Confidential Information that each Party uses to protect its own
information of a confidential and proprietary nature, but in no event less than a reasonable degree of care. Each Party agrees
(i) not to use or disclose any Confidential Information for any purpose outside the scope of this Agreement, (ii) not to reveal
the Confidential Information except to its employees, directors, officers, consultants and staff who have a need to know for the
purpose of this Agreement and the receiving Party agrees that such employees, directors, officers, consultants and staff are bound
by confidentiality obligations at least as stringent as those contained herein, and (iii) except as otherwise authorized by the
other Party in writing, not to disclose any Confidential Information to any third party.

 

		c.	The Parties’ obligation of non-disclosure shall not apply to any
or all information that:

 

		i.	is or becomes public knowledge through no breach of this Agreement by receiving
Party;

		ii.	is disclosed to receiving Party by a third party entitled to disclose such information without
known obligation of confidentiality;

		iii.	is already known or is independently developed by receiving Party without
use of disclosing Party’s Confidential Information as shown by receiving Party’s contemporaneous written records; or

		iv.	is released with the prior written consent of the disclosing Party.

 

		d.	Receiving Party may disclose Confidential Information if required to be disclosed due to applicable
law, court order, statute, or regulation to the extent:

 

		i.	the receiving Party provides the disclosing Party with written notice of
such obligation promptly (prior to the date of legally required disclosure if practicable) so that the disclosing Party can seek
to limit the extent and conditions of such required disclosure; and provided that

 

    5 

     

    

 

		ii.	the receiving Party only discloses that portion of the Confidential Information it is legally
compelled to disclose.

 

		e.	The Parties acknowledge and agree that a breach of the provisions of this
Section 5 might result in immediate and irreparable harm to the business and goodwill of the other Party and that damages, if any,
and remedies at law for such breach might be inadequate and not readily determinable. Upon a breach or threatened breach or violation
of the provisions of this Section 5 the disclosing Party shall be entitled to seek from a court of competent jurisdiction equitable
relief by way of a temporary or permanent injunction to restrain any further breach or violation and such relief as the court may
deem just and proper at law or in equity.

 

		f.	The provisions of this Section shall survive: (i) for a period of five
(5) years after termination or expiration of this Agreement or any Renewal Period for any Confidential Information disclosed under
this Agreement (and not directly related to a specific Work Order); or (ii) for a period of five (5) years after termination or
expiration of the Work Order under which the Confidential Information was disclosed.

 

		6.	Publication Rights. Institution shall have publication privileges in reference to any Study
under this Agreement. Longeveron agrees that the Institution and the Principal Investigator for the Institution shall be permitted
to publish in journals, theses, dissertations, or other formats of their own choosing, and to present at symposia and national
or regional professional meetings, the methods and results of the Study, subject to the following.

 

		a.	At least thirty (30) days in advance of the submission of such proposed
publication or presentation to a journal, editor, or other third party, Institution shall furnish Longeveron copies of the proposed
publication, abstract, theses, dissertations or presentation. The purposes for such prior submission are: (i) to provide Longeveron
with the opportunity to review and comment on the contents of the proposed publication or presentation; (ii) to identify any Confidential
Information of Longeveron to be deleted from the proposed publication or presentation; and (iii) to allow time for any patentable
subject matter to be identified. Longeveron shall provide any comments to Institution within thirty (30) days of receipt of
the proposed publication or presentation. Institution shall give due consideration to any comments made by Longeveron; however,
Institution shall have no obligation to incorporate Longeveron’s comments into the publication.

 

		b.	Institution hereby agrees to delete from the proposed publication any Confidential Information
of Longeveron which Longeveron requests Institution to delete. For the avoidance of doubt,
Institution is not required to delete Study results as long as Institution does not disclose Confidential Information requested
to be deleted by Longeveron.

 

    6 

     

    

 

		c.	Longeveron shall have thirty (30) days after receipt of the proposed publication
or presentation to object to the proposed publication or presentation on the grounds that there is patentable subject matter that
needs protection. In the event Longeveron makes such objection, Institution shall refrain from making such publication or presentation
for no longer than sixty (60) days from the date of receipt of such objection (unless extended by written agreement of the Parties)
in order for patent application(s) directed to the patentable subject matter contained in the proposed publication or presentation
to be filed.

 

		d.	In any publication in connection with the Study, Institution shall acknowledge
the contributions of Longeveron as scientifically appropriate.

 

		7.	Innovation Rights.

 

		a.	Innovations are defined as patentable or un-patentable inventions, discoveries,
processes, compositions, research tools, data, ideas, databases, know-how, copyrightable works that are not scholarly or artistic
Creations and tangible property, including biological organisms, engineering prototypes, drawings, and software created, conceived
or made by either Party within normal duties (including clinical duties), course of studies, field of research or scholarly expertise
or making more than incidental use of that Party’s resources.

 

		b.	For clarity, and except as otherwise expressly provided in this Agreement, neither Longeveron nor
the Institution transfers under this Agreement to the other Party any Innovations owned or controlled by such Party as of the Effective
Date of this Agreement; any existing Longeveron Innovations and Institution Innovations, respectively, shall remain their separate
property, respectively, whether or not protected by patent or other intellectual property rights.

 

		c.	For Innovations conceived, first reduced to
practice or otherwise discovered or developed by either Party or any of such entity’s personnel, whether patentable or not,
in direct connection with or in the direct performance of the collaborative activities under this Agreement, and subject to the
terms of the EXCLUSIVE LICENSE AGREEMENT, the AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT dated December 11, 2017 (the “First
Amendment”) and the AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT dated March 3, 2021 (the “Second Amendment”): i)
Longeveron shall own all Innovations that are conceived, first reduced to practice, or otherwise discovered or developed by Longeveron
or any of its personnel (“Longeveron Innovations”); (ii) Institution shall own all Innovations that are conceived,
first reduced to practice, or otherwise discovered or developed
by Institution or any of its personnel (“Institution Innovations”); and (iii) title to any Innovations made jointly
by Institution and Longeveron will be determined according to U.S. patent law (“Joint Innovations”); if necessary,
the Parties shall select and equally pay for an acceptable third party to determine inventorship of any Joint Innovations.

 

    7 

     

    

 

		d.	With respect to each Institution Innovation and Joint Innovation, Institution
hereby grants to Longeveron an option to negotiate in good faith with Institution for a non- exclusive or an exclusive (at Longeveron’s
discretion), royalty-bearing, worldwide license under Institution’s interest in Institution Innovation and/or Joint Innovation
to develop, make, have made, offer for sale, sell, have sold and import products in a field or fields to be agreed upon by the
Parties on terms that are commercially reasonable to the industry; provided, however, that no such license will include any grant
of exclusive rights that would be inconsistent with the National Institutes of Health’s Principles and Guidelines for Recipients
of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources, as published at 64 Fed. Reg.
72090 (December 23, 1999), and as may be amended from time to time. Longeveron’s option right commences when Institution
notifies Longeveron of such Institution Innovation or Institution’s claim of rights to a Joint Innovation, and expires thirty
(30) days later (“Option Period”). Longeveron may exercise its option right by written notice to the Institution’s
Office of Technology Transfer during the Option Period. If Longeveron does not exercise its option right during the Option Period,
Institution may license its commercial rights under the relevant Institution Innovation to any third parties. If Longeveron exercises
its option right, Institution and Longeveron shall negotiate in good faith a license agreement with commercially reasonable terms.
If the Parties fail to execute a license to Institution Innovation or to Institution’s rights in Joint Innovation within
four (4) months after Institution’s notifying Longeveron of such Innovation, Institution has no further obligation to Longeveron
for that Innovation.

 

		e.	Subject to pre-existing third party and/or US government rights, and consistent with all other
applicable state and federal laws and regulations, Longeveron will be entitled to the following:

 

		i.	A right of first refusal to negotiate an exclusive license for Institution
Innovations arising from research sponsored by Longeveron, with royalty ranges based upon the standard IP value at the time of
licensing. The Parties are amenable to having a mutually acceptable, objective third party to determine the royalty fees to be
paid by Longeveron.

 

		ii.	For any Study sponsored by Longeveron, all participants/potential inventors/Study personnel must
be informed up front regarding Longeveron’s right of first refusal to potential Innovations arising from the applicable Study.

 

    8 

     

    

 

		iii.	For Institution Innovations that arise out of Studies that are not sponsored
by Longeveron, Longeveron may propose terms for an exclusive license, but Longeveron would not be entitled to a right of first
refusal for these Innovations.

 

		8.	Termination.

 

		a.	Termination of this Agreement. Should either Party wish to terminate this Agreement, it
shall provide written notification to the CRADA Committee detailing its concerns or reasons for termination. The CRADA Committee
shall review such details and within thirty (30) days of receipt of the written termination notice propose a potential plan to
address the terminating Party’s concerns or reasons for termination. The terminating Party shall consider in good faith such
plan and, if it determines that such plan is suitable, shall work with the CRADA Committee to implement the plan. However, notwithstanding
the foregoing, should the terminating Party determine such plan is not suitable or does not address its concerns or reasons, it
may terminate this Agreement upon thirty (30) days’ prior written notice to the other Party and the CRADA Committee. Notwithstanding
the above, any Party has the right to terminate this Agreement for its convenience upon sixty (60) days’ prior written notice
to the other Party.

 

		b.	Effect of Termination of this Agreement. Upon termination of this
Agreement, no new Work Orders shall be entered into between the Parties. Notwithstanding the foregoing, the terms of this Agreement
shall survive to complete any Work Order(s) executed prior to termination of this Agreement, and such Work Order(s) shall continue
to be subject to this Agreement until such Work Order(s) are completed or terminated in accordance with the terms therein.

 

		c.	Termination of any Work Order. Should either Party wish to terminate
any Work Order, it may do so by providing written notice to the other Party.

 

		d.	Effect of Termination of any Work Order. In the event that any Work
Order and the applicable Study is terminated prior to its completion, Longeveron shall pay to the Institution the total sums payable
as detailed in the applicable Work Order to this Agreement for the actual work performed as of the date of termination and all
reasonable and necessary non-cancelable expenses, with any unexpended funds previously paid by Longeveron to Institution being
promptly refunded to Longeveron within sixty (60) days of termination of the Work Order. Termination of a Study shall not result
in the termination of the Agreement.

 

		e.	For the avoidance of doubt, the termination of any other agreement between
Institution and Longeveron will be addressed within the terms and conditions of that other agreement. Termination of this Agreement
will not affect the status of those other agreements, and termination of
those other agreements will not affect the status of this Agreement.

 

    9 

     

    

 

		9.	Survival. Termination or expiration of this Agreement will not affect the rights and obligations
of the Parties accrued prior to the termination hereof. The provisions of Section 5, entitled “Confidentiality”, Section
7, entitled “Innovation Rights”, Section 9, entitled “Survival”, Section 10, entitled “Indemnification,
Insurance and Subject Injury”, Section 12, entitled “Publicity”, Section 15, entitled “Governing Law”
and Section 16, entitled “Miscellaneous” shall all survive termination or expiration of this Agreement.

 

		10.	Indemnification, Insurance and Subject Injury.

 

		a.	Longeveron Indemnity. Longeveron agrees to defend, indemnify, and
hold harmless the Institution and its medical affiliates and affiliated hospitals, and each of their trustees, officers, directors,
governing bodies, subsidiaries, affiliates, investigators, employees, institutional review board (“IRB”) members, agents,
successors, heirs and assigns (collectively referred to as “Institution’s Indemnitees”), from and against any
third party claims, loss, damage, cost and expense of claims (including reasonable attorneys’ fees) and suits alleged to
be caused by or arising from (a) the conduct of a Study (and in the case of clinical research, any procedures properly performed
in accordance with the Protocol); (b) the negligent acts or omissions of Longeveron; (c) Longeveron’s failure to adhere to
                                  the terms of this Agreement and/or any applicable Work Order; and/or (d) Longeveron’s use of Institution
                                  Innovations.

		b.	Institution Indemnity. Institution agrees to defend, indemnify,
and hold harmless Longeveron and its trustees, officers, directors, successors, heirs and assigns (collectively referred to as
“Longeverons’s Indemnitees”), from and against any third party claims, loss, damage, cost and expense of claims
(including reasonable attorneys’ fees) and suits alleged to be caused by or arising from (a) the negligent acts or omissions
of Institution; and/or (b) Institution’s failure to adhere to the terms of this Agreement and/or any applicable Work Order.

 

		c.	The indemnified Party shall give notice to the indemnifying Party promptly
upon receipt of written notice of a claim for which indemnification may be sought under this Agreement, provided, however, that
failure to provide such notice shall not relieve indemnifying Party of its indemnification obligations except to the extent that
the indemnifying Party’s ability to defend such claim is materially and adversely affected by such failure. Indemnifying
Party shall not make any settlement admitting fault or incur any liability on the part of the indemnified Party without indemnified
Party’s prior written consent, such consent not to be unreasonably withheld or delayed. The indemnified Party shall cooperate
with indemnifying Party in all reasonable respects regarding the defense of any such claim, at indemnifying
Party’s expense. The indemnified Party shall be entitled to retain counsel of its choice at its own expense. In the event
a claim falls under the above indemnification clauses, in no event shall the indemnified Party compromise, settle or otherwise
admit any liability with respect to any claim without the prior written consent of the indemnifying Party, and such consent not
to be unreasonably withheld or delayed.

 

    10 

     

    

 

		d.	Limitation of Liability. EXCEPT FOR THE PARTIES’ OBLIGATIONS
TO INDEMNIFY EACH OTHER PURSUANT TO THIS AGREEMENT, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR SPECIAL, CONSEQUENTIAL,
INDIRECT, OR INCIDENTAL DAMAGES ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, EVEN IF ADVISED OF THE POSSIBILITY OF THE
SAME.

 

		e.	Insurance.

 

		i.	Longeveron shall maintain the following minimum levels of insurance or self-insurance:
(1) Workers’ Compensation insurance with statutory limits; (2) Employers Liability insurance with limits of not less than
$1,000,000 per occurrence; (3) Commercial General Liability insurance, including blanket contractual liability, with limits of
not less than $2,000,000 per occurrence and $2,000,000 in the aggregate; and (4) Product Liability insurance with limits of not
less than $1,000,000 per occurrence and $2,000,000 in the aggregate. Upon written request, Longeveron shall provide a Certificate
of Insurance to Institution.

 

		ii.	Institution and its employees shall at all times be covered by General Liability
Insurance, with limits of coverage no less than $2,000,000 per occurrence and $2,000,000 annual aggregate and Professional Liability
Insurance with limits of coverage no less than $1,000,000 per occurrence and $3,000,000 in the annual aggregate. Institution may
meet these insurance coverage requirements by self-insured retention coverage, commercial insurance coverage, or a combination
thereof. Evidence of such coverages shall be furnished to Longeveron upon request.

 

		f.	Subject Injury (applicable only for Studies that involve Human Subjects). If a Study
subject suffers an adverse reaction, illness, or injury which, in the reasonable judgment of Institution, was directly caused by
a Study drug or Study device or any properly performed procedures required by the Protocol, Longeveron shall reimburse for the
reasonable and necessary costs of diagnosis and treatment of any Study subject injury, including hospitalization, but only to the
extent such expenses are not attributable to (i) Institution’s negligence or willful misconduct; or (ii) the natural progression
of an underlying or pre-existing condition or events, unless exacerbated by participating in the Study.

 

    11 

     

    

 

		11.	Representations.

 

		a.	Each Party hereby represents to the other Party that:

 

		i.	the Party has full legal right, power and authority to execute, deliver
and perform its obligations under this Agreement;

 

		ii.	the execution, delivery and performance by each Party does not contravene
or constitute a default under any provision of applicable law or its organization documents or under any agreement, judgment, injunction,
order, decree or other instrument binding upon said Party; and

 

		iii.	all licenses, consents, authorizations and approvals, if any, required for the execution, delivery
and performance of this Agreement have been obtained and are in full force and effect and all conditions thereof, if any, will
have been complied with, and no other action by or with respect to, or filing with, any governmental authority or another person
is required in connection with the execution, delivery and performance of this Agreement.

 

		12.	Publicity. Neither Party shall, without the prior written consent of the other Party, use
the name of the other Party, nor of any member of the other Party’s staff, any employee or student of the other Party, nor
any of the other Party’s trademark, logo, symbol, or other image or trade name of the other Party, nor any adaptation of
any of the foregoing, in connection with any products, promotion, articles, press release or other commercial communication or
advertising without the prior written approval of the other Party.

 

		13.	Notice. Any notice or communication pursuant to this Agreement shall
be sufficiently made or given if sent by certified or registered mail, postage prepaid, or by overnight courier, with proof of
delivery by receipt, addressed to the address below or as either Party shall designate by written notice to the other Party.

 

In
the case of Institution, to:

 

University of Miami

Attention: Office of Research Administration

Brandon Strickland, CRA, JD

1320 S. Dixie Highway,

Gables One Tower, Suite # 650,

Coral Gables,
FL 33146

 

    12 

     

    

 

and

 

University of Miami

Attention: U Innovation

Norma Sue Kenyon, Ph.D.

Chief Innovation Officer & Vice Provost
for Innovation

1951 NW 7th Avenue, Suite 310, Locater Code: C234

Miami, FL 33136

 

With copy (which shall not constitute notice)
to

 

University of Miami

Attention: Office of the General Counsel

1320 S. Dixie Highway,

Gables One Tower, Suite # 1250,

Coral Gables,
FL 33146

 

In the case of Longeveron, to:

 

Longeveron, Inc

Geoff Green

President

1951 NW 7th Avenue

Miami, FL 33136

 

and

 

Longeveron, Inc

Paul Lehr

General Counsel

1951 NW 7th Avenue

Miami, FL 33136

 

		15.	Governing Law. This Agreement shall be governed by and construed
in accordance with the laws of the State of Florida notwithstanding any conflicts of laws principles to the contrary, and any suit
to enforce the terms of this Agreement or otherwise arising under this Agreement, shall be brought in the federal or state courts
located within the City of Miami, State of Florida, USA.

 

    13 

     

    

 

		16.	Miscellaneous.

 

		a.	Independent Contractor.

 

		i.	Each of the Parties is an independent contractor and agrees and represents to the other that, except
as contemplated by the provisions of this Agreement, neither will attempt at any time to exercise any significant degree of control
over the other’s efforts in connection with this Agreement.

 

		ii.	Nothing in this Agreement shall be construed to create a partnership or joint venture between the
Parties; nor shall Party’s employees, agents or representatives be considered the employees, agents or representatives of
the other by virtue of this Agreement. Neither Party shall have any express or implied right or authority to assume or create any
obligation on behalf of, or in the name of, the other, or to bind the other to any contract, agreement or undertaking with any
third party.

 

		b.	Entire Agreement. This Agreement, together with all attachments
and exhibits, constitutes the entire agreement and understanding between the Parties and supersedes any prior or contemporaneous
negotiations, agreements, understandings, or arrangements of any nature or kind with respect to the subject matter herein and may
only be amended by written agreement by and between the Parties. In the event of any inconsistency between this Agreement or any
attachments and exhibits, the terms of this Agreement shall govern.

 

		c.	Waiver. Neither Party waives its right to enforce any and all provisions of the Agreement
at any time during the Term. Either Party’s failure to enforce any provision shall not prejudice such Party from later enforcing
or exercising the same or any other provision of the Agreement.

 

		d.	Modifications. This Agreement may not be changed, altered, modified,
amended, rescinded, canceled or waived except by a writing executed by authorized representatives of the Parties.

 

		e.	Binding Agreement on Successors. This Agreement may not be assigned
by either Party without the prior written consent of the other Party. Notwithstanding the above, this Agreement may be assigned
by Institution or Longeveron to a wholly owned subsidiary without consent, but with thirty (30) days’ prior written notice
to the other Party.

 

		f.	Headings. Headings are for convenience of reference only, and not
for interpreting the provisions of the Agreement.

 

		g.	Counterparts. Execution signatures to this Agreement may be exchanged as scanned
                                                             e-mail attachments and all signatures so exchanged shall be considered as original for all purposes. Facsimiles or scanned
                                                             copies of signatures or electronic images of signatures shall be considered original signatures unless prohibited by applicable law. This Agreement
may be executed in counterparts, and by either Party on a separate counterpart, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

    14 

     

    

  

IN WITNESS WHEREOF, the parties have caused
this Agreement to be executed by their respective duly authorized representatives as of the date first above written.

 

	Longeveron, Inc.	 
	 	 
	By: 	/s/ Geoff Green	 
	Name: 	Geoff Green	 
	Title: 	Chief Executive Officer	 
	Date: 	March 14, 2021	 
	 	 
	University of Miami	 
	 	 
	By: 	/s/ K. Brandon Strickland	 
	Name: 	Brandon Strickland	 
	Title: 	Executive Director, Office of Research Administration
	Date: 	March 3, 2021	 

  

    15 

     

    

 

Exhibit A

 

Work Order
Template

 

WORK ORDER

 

This Work Order is made pursuant
to the COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT entered into by and between Longeveron, Inc, a Delaware corporation
whose principal place of business is at 1951 NW 7th Avenue, Miami, Florida 33136 (“Longeveron”), and the University
of Miami, having an address at 1320 S. Dixie Highway, Gables One Tower #650, Locator Code 2960, Coral Gables, FL 33146 (the
“Institution”) dated(the “Agreement”) which is incorporated by reference herein and made part
of this Work Order.

 

PROJECT INFORMATION

 

	Principal Investigator:
	Protocol/Study #:
	Study Type:	
        ☐  Applied
        Research ☐ Basic Research

        ☐ Animal
        Research ☐ Human Subject Research  ☐ Clinical Trial

	Effective Period Start Date: Termination Date:

 

NOTICE

 

In addition to Notices provided
under Section 13 of the Agreement, the following notices shall be provided pursuant to this Work Order in accordance with the terms
outlined in Section 13 of the Agreement:

 

For Institution Principal Investigator:

 

	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

MODIFICATIONS AND ADDITIONAL TERMS FOR THIS WORK
ORDER (if none, add “N/A”)

 

	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

LIST OF ATTACHMENTS AND PROTOCOL

 

	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

  

COSTS AND PAYMENT

 

A.
Payment shall be made to the Institution in accordance with the Schedule A appended hereto and incorporated herein by reference.

 

B. Each check will be made payable to University of Miami, will reference the Protocol number and will be mailed to the address
set forth in Schedule A. The Institution’s Tax Identification Number is 59- 0624458.

 

     

     

    

  

IN WITNESS WHEREOF, the Parties have executed
this Work Order by their duly authorized officers or representatives.

 

	UNIVERSITY OF MIAMI	 	LONGEVERON, Inc.
	 	 	 	 	 
	Signed	              	 	Signed	              
	Name:	 	 	Name:	 
	Position:	 	 	Position: 	 
	 	 	 	 	 
	Dated:	 	 	Dated: 	 

 

READ AND UNDERSTOOD: 

PRINCIPAL INVESTIGATOR

I have read this Work Order and the 

Collaborative
Research and Development

 Agreement, and I understand and accept 

my obligations hereunder.

 

	Signed	              	 
	Name:	 	 
	Dated:	 	 

 

     

     

    

 

Schedule A

 

Protocol/Statement of Work

 

 

     

     

    

 

Schedule B

 

Budget

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}]]